Of the three highest bidders, Pfizer’s purchase proposal for Metsera was the lowest, regulatory documents reveal. The New ...

The Pfizer stake now accounts for 5.2% of Wilsey’s U.S. equity portfolio, placing it outside the fund’s top five holdings.

Pfizer has re-entered the obesity drug sector by acquiring Metsera, Inc., having successfully outmaneuvered six other bidders ...

Pfizer acquires Metsera to enter the booming obesity drug market with next-gen GLP-1 therapies. Find out why PFE stock is a ...

President Donald Trump and Pfizer's CEO today announced "TrumpRX" and lower drug prices. But what does Pfizer sell? Here's ...

Pfizer acquired a smaller company for $4.9 billion to improve its prospects in the GLP-1 market. The pharmaceutical giant could carve out a small niche for itself in this growing space.

Pfizer (PFE -3.36%) continues to lag the market. Over the past few years, the company has generally reported declining revenue and profits, resulting in a substantial decline in m ...

Pfizer (NYSE: PFE) has a huge 7.1% dividend yield. That certainly compares favorably to the broader market's 1.2% yield and ...

Moderna and Pfizer-BioNTech are in a tight race to launch their COVID-19 vaccines in Europe after both applied for emergency EU approval on Tuesday, though there was uncertainty over whether a rollout ...

So, a total of $1.9 billion in cost savings, which is modest compared to a market size of $590 billion for pharmaceuticals in ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $29.25, a high estimate of $33.00, and a low estimate of $26.00. Marking an ...